CALGARY, Feb. 16, 2021 – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, announced today the official opening of the ATMA Calgary Urban Journey Clinic, a facility located in central Calgary featuring 5,000 square feet of healing, transformative and training space.

ATMA’s Calgary Journey Clinic is Canada’s first non-ketamine psychedelic therapy clinic, and will be home to the National Psychedelic Training Center where mental health care professionals from across the country will be trained to deliver leading-edge therapy services that incorporate the latest research, science and best practices.

David Harder, Co-CEO of ATMA, said: “Today is the result of years of passion, planning and commitment to a vision of bringing the potential of psychedelics into the Canadian mental health system. It is both humbling and exciting to see how the merits of psychedelic medicine are driving the acceleration of not just ATMA, but the overall psychedelic industry here in Canada and around the world.”

ATMA was the first private company in Canada to conduct legal psychedelic-assisted therapy with psilocybin, the result of ATMA being selected by Alberta’s first palliative patient to be granted a Section 56 Exemption by Health Canada to undergo the therapy.

Added Harder: “Being able to assist individual patients with psychedelic-assisted therapy at our Calgary Journey Clinic will help us directly impact the quality of lives of each individual undergoing therapy. Launching the National Psychedelic Training Center will also magnify the impact we can have even further by equipping Canadian therapists to provide this extraordinary solution across Canada as legal access to psychedelic medicine expands.”

The company has already scheduled upcoming therapy sessions at the Calgary facility for additional patients that have received their own Section 56 Exemptions and continues to work with other leaders in the industry to maximize client access to therapy and support.

Members of the ATMA Medical Team, including Chief Medical Officer Dr. Ravi Bains and Palliative Care Medical Advisor Dr. Lyle Galloway have been working with the company’s palliative care patients in all aspects of medical oversight, pre-therapy preparation and counselling sessions.

The door to legal Canadian psychedelic medicine was opened in August 2020 when Dr. Bruce Tobin, a Victoria-based psychotherapist who founded the non-profit TheraPsil, was successful in assisting a palliative care patient to obtain the first Section 56 Exemption on record for psychedelic-assisted therapy. Since that watershed moment, his tireless efforts have led to the modern renaissance of psychedelic medicine across the country.

ATMA has recently opened an application process for Canadians who wish to apply for assistance in submitting a Section 56 Exemption to Health Canada. To date, Health Canada has limited the granting of Section 56 Exemptions to palliative care patients facing a terminal illness, but there is growing optimism that Health Canada will expand its scope of exemptions to include other pressing treatment-resistant conditions such as PTSD, depression, anxiety and addiction.

Any Canadian who meets the eligibility criteria may initiate the application process for assistance to obtain a Section 56 Exemption by visiting ATMA’s website at www.atmajourney.com prior to March 12th, 2021.

More News and Media:

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Is Training in Psychedelics Worth It?

Let’s start with a brief review of psychedelics, including what they are and how they differ from conventional Western medicine. There are many substances under the umbrella of psychedelics; the common ones are: Psilocybin (the active ingredient in magic mushrooms)  LSD (lysergic acid diethylamide) Ibogaine (the active ingredient in iboga) Mescaline (the active ingredient in

ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-Related Mental Wellness Challenges.

CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of its innovative psychedelic-assisted therapy solutions, announced the submission of its N-500 Phase II Psilocybin Clinical Trial to Health Canada today. This trial is aimed at studying the potential relief of COVID-19-associated mental health concerns in healthcare professionals, as well

Scroll to Top